ORIC Pharmaceuticals logo

ORIC PharmaceuticalsNASDAQ: ORIC

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

24 April 2020

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$663.80 M
-38%vs. 3y high
69%vs. sector
-vs. 3y high
-vs. sector
-54%vs. 3y high
60%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 45 min ago
$9.41+$0.05(+0.53%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ORIC Latest News

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com01 November 2024 Sentiment: -

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 1, 2024 (the “Grant Date”), ORIC granted a total of 61,800 non-qualified stock options and 10,400 restricted stock units to two new non-executive employees who began their employment with ORIC in October 2024.

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
globenewswire.com09 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 23-25, 2024, in Barcelona, Spain.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com04 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2024 (the “Grant Date”), ORIC granted a total of 92,400 non-qualified stock options and 16,300 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2024.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com06 September 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 3, 2024 (the “Grant Date”), ORIC granted a total of 173,200 non-qualified stock options and 28,900 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2024.

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com26 August 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September:

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
globenewswire.com05 August 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com02 August 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2024 (the “Grant Date”), ORIC® granted a total of 33,000 non-qualified stock options and 5,600 restricted stock units to two new non-executive employees who began their employment with ORIC® in July 2024.

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
globenewswire.com16 July 2024 Sentiment: POSITIVE

ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com05 July 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2024 (the “Grant Date”), ORIC granted a total of 34,000 non-qualified stock options and 5,600 restricted stock units to three new non-executive employees who began their employment with ORIC in June 2024.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com07 June 2024 Sentiment: NEUTRAL

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 3, 2024 (the “Grant Date”), ORIC granted a total of 30,000 non-qualified stock options and 4,800 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2024.

  • 1(current)

What type of business is ORIC Pharmaceuticals?

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

What sector is ORIC Pharmaceuticals in?

ORIC Pharmaceuticals is in the Healthcare sector

What industry is ORIC Pharmaceuticals in?

ORIC Pharmaceuticals is in the Biotechnology industry

What country is ORIC Pharmaceuticals from?

ORIC Pharmaceuticals is headquartered in United States

When did ORIC Pharmaceuticals go public?

ORIC Pharmaceuticals initial public offering (IPO) was on 24 April 2020

What is ORIC Pharmaceuticals website?

https://www.oricpharma.com

Is ORIC Pharmaceuticals in the S&P 500?

No, ORIC Pharmaceuticals is not included in the S&P 500 index

Is ORIC Pharmaceuticals in the NASDAQ 100?

No, ORIC Pharmaceuticals is not included in the NASDAQ 100 index

Is ORIC Pharmaceuticals in the Dow Jones?

No, ORIC Pharmaceuticals is not included in the Dow Jones index

When was ORIC Pharmaceuticals the previous earnings report?

No data

When does ORIC Pharmaceuticals earnings report?

The next expected earnings date for ORIC Pharmaceuticals is 06 November 2024